Blocking fgf2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings

Blocking fgf2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings

Author de Aguiar, Rodrigo Barbosa Autor UNIFESP Google Scholar
Parise, Carolina Bellini Autor UNIFESP Google Scholar
Teixeira Souza, Carolina Rosal Google Scholar
Braggion, Camila Autor UNIFESP Google Scholar
Quintilio, Wagner Google Scholar
Moro, Ana Maria Google Scholar
Navarro Marques, Fabio Luiz Google Scholar
Buchpiguel, Carlos Alberto Google Scholar
Chammas, Roger Google Scholar
de Moraes, Jane Zveiter Autor UNIFESP Google Scholar
Abstract Compelling evidence suggests that fibroblast growth factor 2 (FGF2), overexpressed in melanomas, plays an important role in tumor growth, angiogenesis and metastasis. In this study, we evaluated the therapeutic use of a new anti-FGF2 monoclonal antibody (mAb), 3F12E7, using for that the B16-F10 melanoma model. The FGF2 neutralizing effect of this antibody was certified by in vitro assays, which allowed the further track of its possible in vivo application. 3F12E7 mAb could be retained in B16-F10 tumors, as shown by antibody low-pH elution and nuclear medicine studies, and also led to reduction in number and size of metastatic foci in lungs, when treatment starts one day after intravenous injection of B16-F10 cells. Such data were accompanied by decreased CD34(+) tumor vascular density and impaired subcutaneous tumor outgrowth. Treatments starting one week after melanoma cell intravenous injection did not reduce tumor burden, remaining the therapeutic effectiveness restricted to early-adopted regimens. Altogether, the presented anti-FGF2 3F12E7 mAb stands as a promising agent to treat metastatic melanoma tumors in adjuvant settings. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Keywords Fgf2
Melanoma
Monoclonal Antibody
Angiogenesis
MetastasisEndothelial Growth-Factor
Human-Malignant Melanoma
Tumor-Growth
Antigen Cea
In-Vivo
Bevacizumab
Cells
Progression
Expression
Therapy
Language English
Sponsor FAPESP [98/14247-6, 09/18631-1, 13/06120-8]
CAPES
CNPq [11934/2013-7]
CAPES-UDELAR research grants
Grant number FAPESP: 98/14247-6
FAPESP: 09/18631-1
FAPESP: 13/06120-8
CAPES: RBA
capes: CBP
capes: CB
CNPq: CRTS
CNPq: AMM, 11934/2013-7
Date 2016
Published in Cancer Letters. Clare, v. 371, n. 2, p. 151-160, 2016.
ISSN 0304-3835 (Sherpa/Romeo, impact factor)
Publisher Elsevier ireland ltd
Extent 151-160
Origin https://doi.org/10.1016/j.canlet.2015.11.030
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000370457300002
URI http://repositorio.unifesp.br/handle/11600/49604

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account